IPHP Stock Financial Analysis - Innate Pharma S.A. (BATS-CHIXE) Stock

Overview

Innate Pharma S.A. is a biotechnology company based in Marseille, France, that specializes in developing novel therapeutic antibodies for the treatment of oncology indications. The company's primary focus is on harnessing the power of the immune system to create new treatments for cancer. Innate Pharma has a diverse portfolio of clinical and preclinical stage projects, including the development of Monalizumab, a first-in-class antibody targeting NKG2A receptors on Natural Killer cells and T cells, and Lacutamab, an antibody targeting the KIR3DL2 receptor on certain lymphomas.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The revenue for Innate Pharma S.A. as of 31 December 2024 is 20.12 MM.
The operating income for Innate Pharma S.A. as of 31 December 2024 is -51.58 MM.
The net income for Innate Pharma S.A. as of 31 December 2024 is -49.47 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2024-12-31	20.12	-51.58	-49.47
2024-09-30	26.95	-45.08	-41.76
2024-06-30	33.79	-38.58	-34.05
2024-03-31	47.71	-25.63	-20.81
2023-12-31	61.64	-12.67	-7.57
2023-09-30	56.96	-18.99	-35.13
2023-06-30	52.28	-25.32	-62.69
2023-03-31	54.98	-20.87	-60.40
2022-12-31	57.67	-16.43	-58.10
2022-09-30	57.33	-17.61	-40.45
2022-06-30	56.98	-18.79	-22.79
2022-03-31	40.84	-33.31	-37.80
2021-12-31	24.70	-47.83	-52.81
2021-06-30	46.34	-11.11	-77.37
2021-03-31	58.06	-5.02	-70.68
2020-12-31	69.77	1.08	-63.98
2020-09-30	66.93	-31.70	-54.16
2020-06-30
2020-03-31

Income Statement: EPS

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2024-12-31
2024-09-30
2024-06-30	-0.42	-0.42
2024-03-31	-0.26	-0.26
2023-12-31	-0.09	-0.09
2023-09-30	-0.44	-0.44
2023-06-30	-0.78	-0.79
2023-03-31	-0.76	-0.76
2022-12-31	-0.73	-0.73
2022-09-30	-0.51	-0.51
2022-06-30	-0.29	-0.28
2022-03-31	-0.47	-0.47
2021-12-31	-0.66	-0.66
2021-06-30	-0.98	-0.98
2021-03-31	-0.90	-0.89
2020-12-31	-0.81	-0.81
2020-09-30	-0.71	-0.71
2020-06-30	-0.60	-0.59
2020-03-31	-0.46	-0.46

Cash Flow: Operations, Investing, Financing

The cash from operating activities for Innate Pharma S.A. as of 31 December 2024 is -6.90 MM.
The cash from investing activities for Innate Pharma S.A. as of 31 December 2024 is 9.20 MM.
The cash from financing activities for Innate Pharma S.A. as of 31 December 2024 is -6.01 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2024-12-31	-6.90	9.20	-6.01
2024-09-30	-12.48	15.50	-5.53
2024-06-30	-18.06	21.81	-5.05
2024-03-31	-25.31	21.22	-3.51
2023-12-31	-32.56	20.63	-1.97
2023-09-30	-32.20	11.33	-2.04
2023-06-30	-31.84	2.03	-2.11
2023-03-31	-25.50	1.95	-1.97
2022-12-31	-19.16	1.88	-1.83
2022-09-30	-22.62	0.41	12.63
2022-06-30	-26.08	-1.06	27.08
2022-03-31	-42.27	-0.99	26.95
2021-12-31	-58.46	-0.92	26.82
2021-06-30	-24.90	-1.51	-1.20
2021-03-31	-38.34	-7.44	-1.19
2020-12-31	-51.77	-13.37	-1.18
2020-09-30	-67.25	-12.90	38.08
2020-06-30
2020-03-31

Valuation Metrics : PE, PriceToBook, PriceToTBV

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31

Management Effectiveness

The roa for Innate Pharma S.A. as of 31 December 2024 is -0.18.
The roe for Innate Pharma S.A. as of 31 December 2024 is -0.95.
The roic for Innate Pharma S.A. as of 31 December 2024 is -0.53.
The croic for Innate Pharma S.A. as of 31 December 2024 is -0.02.
The ocroic for Innate Pharma S.A. as of 31 December 2024 is -0.28.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2024-12-31	-0.18	-0.95	-0.53	-0.02	-0.28
2024-09-30	-0.18	-0.80	-0.53	-0.02	-0.28
2024-06-30	-0.10	-0.36	-0.32	-0.12	-0.39
2024-03-31	-0.04	-0.14	-0.08	-0.15	-0.35
2023-12-31	-0.17	-0.65	-0.35	-0.23	-0.32
2023-09-30	-0.22	-0.54	-0.63	-0.32	-0.32
2023-06-30	-0.22	-0.54	-0.63	-0.32	-0.32
2023-03-31	-0.22	-0.52	-0.61	-0.26	-0.26
2022-12-31	-0.15	-0.38	-0.41	-0.10	-0.23
2022-09-30	-0.15	-0.38	-0.41	-0.10	-0.23
2022-06-30	-0.09	-0.17	-0.14	-0.01	-0.16
2022-03-31	-0.14	-0.28	-0.24	-0.11	-0.26
2021-12-31	-0.17	-0.34	-0.34	-0.21	-0.38
2021-06-30	-0.23	-0.37	-0.50	-0.18	-0.16
2021-03-31	-0.21	-0.34	-0.46	-0.31	-0.25
2020-12-31	-0.16	-0.29	-0.36	-0.37	-0.29
2020-09-30	-0.13	-0.25	-0.30	-0.23	-0.38
2020-06-30	-0.13	-0.24	-0.20	-0.08	-0.37
2020-03-31	-0.09	-0.18	-0.14	0.07	-0.11

Gross Margins

The gross margin for Innate Pharma S.A. as of 31 December 2024 is -0.59.
The net margin for Innate Pharma S.A. as of 31 December 2024 is -1.01.
The operating margin for Innate Pharma S.A. as of 31 December 2024 is -1.14.

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2024-12-31	-0.59	-1.01	-1.14
2024-09-30	-0.59	-1.01	-1.14
2024-06-30	-0.15	-0.44	-0.54
2024-03-31	0.09	-0.12	-0.21
2023-12-31	-0.00	-0.62	-0.33
2023-09-30	-0.11	-1.20	-0.48
2023-06-30	-0.11	-1.20	-0.48
2023-03-31	0.00	-1.10	-0.38
2022-12-31	0.11	-0.71	-0.31
2022-09-30	0.11	-0.71	-0.31
2022-06-30	0.11	-0.40	-0.33
2022-03-31	-0.20	-0.93	-0.82
2021-12-31	-0.90	-2.14	-1.94
2021-06-30	0.01	-1.57	-0.72
2021-03-31	0.10	-1.18	-0.45
2020-12-31	0.29	-0.92	0.02
2020-09-30	0.01	-0.81	-0.47
2020-06-30	-0.16	-0.70	-0.71
2020-03-31	-0.02	-0.44	-0.48

IT:4IPH
FR:IPH	€1.77
GB:0EVI	€1.79
US:IPHYF
DE:IDD	€1.84